source
- Definium Therapeutics clinches third phase-3 win for LSD anxiety drug, eyes FDA filingDefinium Therapeutics reported another successful phase 3 trial of its LSD‑based anxiety treatment, DT120 ODT. The Panorama study enrolled 245 patients and compared a 100 µg dose of DT120 with pla…
- Novartis shares tumble 13% after three late-stage drug setbacks hit marketNovartis' stock dropped more than 13% this week after three of its late-stage programs reported setbacks, pulling down other pharma stocks. The antibody-oligonucleotide conjugate del-desiran faile…